Acute leukemia in middle Norway 1984-88

Area of Science:

• Hematology
• Oncology
• Epidemiology

Background:

• Acute leukemia incidence in middle Norway (1984-1988) was 4.6/100,000.
• The study cohort comprised 108 adult patients: 9 acute lymphoblastic leukemia (ALL), 93 acute myeloid leukemia (AML), and 6 unclassified acute leukemias.

Purpose of the Study:

• To determine the incidence and long-term survival rates of acute leukemia in a Norwegian population.
• To evaluate the efficacy of different treatment strategies for acute myeloid leukemia.

Main Methods:

• Retrospective analysis of 108 adult acute leukemia patients diagnosed between 1984-1988.
• Patients were categorized by leukemia type, age, and treatment received (cytotoxic drugs, aplasia-inducing regimens, oral drugs, low-dose ara-C).
• Survival, remission rates, and remission duration were tracked for over 5 years.

Main Results:

• Overall 5-year survival for all acute leukemias was 11.1% (12/108).
• For AML patients receiving intravenous aplasia-inducing drugs, the remission rate was 65%, with a median remission duration of 12.2 months and a 5-year survival of 19%.
• Younger AML patients (median age 41) on intensive chemotherapy showed a 5-year survival of 32% and a 5-year relapse-free survival of 32%.

Conclusions:

• Acute myeloid leukemia (AML) treatment outcomes varied significantly based on age and therapeutic approach.
• Intensive chemotherapy demonstrated improved long-term survival and relapse-free survival for younger AML patients.
• Further research into optimized treatment protocols for AML is warranted.